Chronic kidney disease (CKD) has become a global health issue, affecting up to 14% of the population worldwide. Between 1990 and 2021, the number of patients grew from 351 million to almost 674 million, with projections warning that CKD may rank as the fifth leading cause of death globally by 2040. Clinically, CKD stems from a complex mix of etiologies, including lifestyle-driven civilization diseases, such as diabetes, hypertension, or obesity, immune-mediated glomerulonephritides (such as IgA, membranous nephropathy or focal segmental glomerulosclerosis), genetic (such as autosomal-dominant polycystic kidney disease, Fabry disease) and tubulointerstitial diseases, or causes of undetermined etiology. Time to diagnosis and the diagnosis of CKD before end-stage organ failure are crucial; therefore, new methods are actively being developed for early detection of kidney disease. Physicians emphasize the need to evaluate markers of kidney dysfunction faster and more accurately. Modern nephrology relies on multi-omics profiling, encompassing genomics, transcriptomics, proteomics, and metabolomics. Applying these technologies to identify molecular drivers of the disease can yield specific signatures that help clinicians stratify patients and decide on a treatment and follow-up plan. Our review addresses a fundamental transformation reshaping nephrology: the transition from a traditional to precision medicine approach.
21 September 2026 in International Journal of Innovative Technologies in Social Science
Introduction: Pain remains one of the most prevalent health problems worldwide and a major cause of disability, reduced quality of life and healthcare utilization. Although opioid analgesics have long been considered the cornerstone of treatment for moderate-to-severe pain, their use is associated with substantial risks, including tolerance, dependence, addiction and overdose. Consequently, the development of effective non-opioid analgesics has become a priority in pain medicine. Suzetrigine (VX-548), a selective voltage-gated sodium channel NaV1.8 inhibitor, has recently emerged as a promising therapeutic option for acute pain management. Purpose: The aim of this review is to evaluate the current evidence regarding suzetrigine as a novel non-opioid analgesic and to discuss its potential role in the future of pain management. Particular attention is given to the clinical burden of pain, the limitations of existing analgesic therapies, the biological rationale for targeting NaV1.8 channels, and the efficacy and safety of suzetrigine. Methodology: A narrative review of literature was conducted using published preclinical studies, clinical trials, review articles, systematic reviews and meta-analyses concerning suzetrigine and NaV1.8 inhibition using PubMed and Clinicaltrials.gov. The reviewed literature included studies evaluating pharmacological properties, mechanism of action, clinical efficacy, safety profile and potential therapeutic applications of suzetrigine in acute and chronic pain conditions. Conclusion: Current evidence indicates that suzetrigine represents a significant advancement in analgesic drug development. By selectively inhibiting NaV1.8 channels involved in peripheral nociceptive signaling, it provides effective pain relief without engaging opioid pathways. Clinical studies have demonstrated favorable efficacy and tolerability in patients, with moderate-to-severe acute pain, while ongoing research continues to explore its potential applications in chronic and disease-specific pain conditions. Suzetrigine may therefore contribute to reducing reliance on opioid analgesics and represents a promising step toward safer pain management strategies.
17 September 2026 in International Journal of Innovative Technologies in Social Science
Background: Vein of Galen aneurysmal malformations (VGAMs) represent a complex and rare subset of congenital arteriovenous anomalies, comprising approximately 30% of all pediatric cerebral vascular malformations. Originating during early embryogenesis between the 6th and 11th weeks of gestation, these lesions create a low-resistance, high-flow shunt. Consequently, they frequently precipitate life-threatening complications, most notably high-output heart failure and severe neurological compromise in the immediate postnatal period, necessitating prompt and accurate diagnostic strategies. Aim: The primary objective of this study is to elucidate the critical, first-line diagnostic and monitoring role of bedside transfontanellar ultrasonography in the management of neonatal VGAMs. Additionally, we aim to contextualize these clinical findings within a comprehensive review of the current literature, emphasizing recent paradigm shifts in neurointensive care and endovascular therapies. Material and methods: We report the clinical case of a 4-week-old male newborn admitted to the emergency department with recurrent generalized seizures, progressive macrocephaly, and profound perioral cyanosis. A detailed clinical evaluation was conducted, prioritizing bedside neurosonography. This clinical presentation is supplemented by a comprehensive literature review exploring the evolving landscape of VGAM management, including molecular genetics and fetal interventions. Results: Urgent transfontanellar ultrasonography augmented by color Doppler identified a prominent hypoechoic arteriovenous malformation demonstrating high-velocity turbulent flow. This was accompanied by secondary findings of lateral ventricle dilatation and diffuse parenchymal calcifications indicative of chronic ischemic injury. The precise neurovascular architecture was subsequently verified via Magnetic Resonance Imaging (MRI). Following multidisciplinary conservative management to allow for infant growth, the patient successfully underwent transarterial embolization at 7 months of age. A follow-up ultrasound at 9 months confirmed a significant reduction in arteriovenous shunting and stabilization of the cerebral structures. Conclusions: Bedside transfontanellar ultrasonography serves as an indispensable, non-invasive, and radiation-free modality for the rapid identification, hemodynamic profiling, and serial follow-up of VGAMs in critically ill neonates. Its integration with advanced, staged endovascular techniques and emerging prenatal in utero interventions fundamentally transforms the clinical trajectory of this historically fatal congenital defect.
21 September 2026 in International Journal of Innovative Technologies in Social Science
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation of the colon resulting from immune dysregulation. Despite the availability of multiple therapeutic options, a substantial proportion of patients fail to achieve sustained remission or develop loss of response to existing therapies. Increasing evidence has identified the interleukin-23 (IL-23)/Th17 pathway as a key mechanism involved in the pathogenesis of UC, leading to the development of selective IL-23 inhibitors as novel therapeutic agents. Purpose: The aim of this study was to review and summarize current evidence regarding the efficacy and safety of IL-23 inhibitors, particularly mirikizumab, risankizumab and guselkumab, in the treatment of moderate-to-severe ulcerative colitis. Methodology: A narrative literature review was performed using PubMed and ClinicalTrials.gov to identify relevant studies investigating IL-23 inhibitors in the treatment of ulcerative colitis. The review included phase II and phase III randomized controlled trials, long term extension studies, real-world observational cohorts, systematic reviews and meta-analyses. Data were extracted and synthesized to provide a comprehensive assessment of the efficacy, safety and evolving therapeutic role of IL-23 inhibitors in ulcerative colitis. Conclusions: Available evidence indicates that IL-23 inhibitors are effective therapeutic options for patients with moderate-to-severe ulcerative colitis. Mirikizumab, risankizumab and guselkumab demonstrated significant improvements in clinical remission, endoscopic healing, histologic outcomes and quality of life. Among these agents, mirikizumab currently has the strongest evidence supporting long-term efficacy and durability of response. IL-23 inhibitors also demonstrated favorable safety profiles, with low rates of serious adverse events and treatment discontinuation. Although further real-world data and head-to-head comparative studies are still needed, selective IL-23 blockade represents a promising advancement in personalized UC treatment strategies.
Cardiovascular disease remains the leading cause of mortality in kidney transplant recipients (KTRs). Arterial hypertension is present in a vast majority of patients after kidney transplantation, constituting the most prevalent cardiovascular comorbidity, and is a significant modifiable risk factor for other cardiovascular complications and graft loss. The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not address blood pressure control strategies in KTRs, and the prior 2021 KDIGO recommendations targeting values below 130/80 mmHg rely primarily on data extrapolated from non-KTR populations. This represents an existing evidence gap in the management of post-transplant hypertension. Dihydropyridine calcium channel blockers and angiotensin receptor blockers remain first-line antihypertensive medications, although most studies assessing their effectiveness in KTRs date back more than 15 years. The current treatment guidelines are based largely on limited and outdated data. Optimal selection and individualization of immunosuppressive therapy and—when feasible—its modification in some KTRs may be important in improving blood pressure control. This includes, for example, a reduction in the calcineurin inhibitor or steroid dose, as well as the use of mTOR inhibitors or belatacept. The lack of large, up-to-date randomized trials in the KTR population underscores the pressing need for further extensive research focused on this patient group.